Clinical trials of sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists have shown beneficial effects of these agents on kidney outcomes in patients with type 2 diabetes mellitus. Two new cohort studies now demonstrate that these findings are generalizable to the broad range of patients seen in clinical practice.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Zelniker, T. A. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393, 31–39 (2019).
Kristensen, S. L. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 7, 776–785 (2019).
Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).
Giorgino, F., Vora, J., Fenici, P. & Solini, A. Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: does it apply to all patients? Diabetes Obes. Metab. https://doi.org/10.1111/dom.14055 (2020).
Birkeland, K. I. et al. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Diabetes Obes. Metab. 21, 968–974 (2019).
Knudsen, J. S., Thomsen, R. W., Pottegård, A., Knop, F. K. & Sørensen, H. T. Differences between randomized clinical trial patients and real-world initiators of the glucagon-like peptide 1 receptor agonist liraglutide. Diabetes Care 41, e133–e135 (2018).
Pasternak, B. et al. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. Br. Med. J. 369, m1186 (2020).
Pasternak, B. et al. Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. Diabetes Care 43, 1326–1335 (2020).
Heerspink, H. J. L. et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 8, 27–35 (2020).
Heerspink, H. J. L. et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol. Dial. Transplant. 35, 274–282 (2020).
H.L.H. has served as a consultant for AbbVie, Astellas, AstraZeneca, Boehringer Ingelheim, Fresenius, Gilead, Janssen, Merck, Mundipharma, Mitsubishi Tanabe, and Retrophin and has received grant support from AbbVie, AstraZeneca, Boehringer Ingelheim, and Janssen. A.B.v.d.A-v.d.B. declares no competing interests.
About this article
Cite this article
van der Aart-van der Beek, A.B., Heerspink, H.J.L. Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice. Nat Rev Nephrol 16, 433–434 (2020). https://doi.org/10.1038/s41581-020-0312-7
This article is cited by
Reversal of the renal hyperglycemic memory in diabetic kidney disease by targeting sustained tubular p21 expression
Nature Communications (2022)
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
Cardiovascular Diabetology (2020)